Efficacy and safety of topical spironolactone versus topical dapsone in the treatment of acne vulgaris.
Acne
Acne vulgaris
Dapsone
Spironolactone
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
22
06
2024
accepted:
30
09
2024
revised:
14
09
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Acne vulgaris is a common skin disease that greatly impacts the quality of life of affected individuals. Several treatment modalities are available for acne, with variable degrees of success. Our aim was to compare the safety and efficacy of topical spironolactone 5% gel and topical dapsone 5% gel as treatment modalities for acne vulgaris. The study included 28 patients with mild to moderate acne. They were randomly divided into two equal groups. Group I treated with topical spironolactone 5% gel, and group II treated with topical dapsone 5% gel. In both groups, the gel was applied twice daily for 12 weeks, and patients were evaluated using the acne severity index. Group I included 14 patients [11 (78.6%) females and 3 (21.4%) males]. More than one-half of this group (64.3%) had moderate acne severity. Group II included 14 patients [12 (85.7%) females and 2 (14.3%) males]. Half of patients had moderate acne severity. Therapeutic response was poor, moderate, good, and excellent (14.3%), (28.6%), (50%), (7.1%), respectively, in topical spironolactone group versus poor, moderate, and good (50%), (42.9%), (7.1%), respectively, in topical dapsone group. The therapeutic response between the studied groups was statistically significant in favor of the topical spironolactone group. Regarding adverse effects, burning sensation was evident after application of topical spironolactone while itching was significantly common with topical dapsone. The data provided by the current study support the use of topical spironolactone 5% gel in treating acne vulgaris in both male and female patients.
Identifiants
pubmed: 39485505
doi: 10.1007/s00403-024-03430-1
pii: 10.1007/s00403-024-03430-1
doi:
Substances chimiques
Dapsone
8W5C518302
Spironolactone
27O7W4T232
Gels
0
Types de publication
Journal Article
Randomized Controlled Trial
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
732Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Keyal U, Bhatta AK, Wang XL (2016) Photodynamic therapy for the treatment of different severity of acne: a systematic review. Photodiagnosis Photodyn Ther 14:191–199. https://doi.org/10.1016/j.pdpdt.2016.04.005
doi: 10.1016/j.pdpdt.2016.04.005
pubmed: 27090488
Tan JK, Bhate K (2015) A global perspective on the epidemiology of acne. Br J Dermatol 172 Suppl 1:3–12. https://doi.org/10.1111/bjd.13462
doi: 10.1111/bjd.13462
Fabbrocini G, Annunziata MC, D’Arco V et al (2010) Acne scars: pathogenesis, classification and treatment. Dermatol Res Pract 2010:893080. https://doi.org/10.1155/2010/893080
doi: 10.1155/2010/893080
pubmed: 20981308
pmcid: 2958495
Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L (2011) Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol 131(2):363–370. https://doi.org/10.1038/jid.2010.264
doi: 10.1038/jid.2010.264
pubmed: 20844551
Zaenglein AL, Pathy AL, Schlosser BJ et al (2016) Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 74(5):945–73e33. https://doi.org/10.1016/j.jaad.2015.12.037
doi: 10.1016/j.jaad.2015.12.037
pubmed: 26897386
Searle T, Al-Niaimi F, Ali FR (2021) Dapsone for acne: still in use after half a century! J Cosmet Dermatol 20(7):2036–2039. https://doi.org/10.1111/jocd.14011
doi: 10.1111/jocd.14011
pubmed: 33600049
Ghaoui N, Hanna E, Abbas O, Kibbi AG, Kurban M (2020) Update on the use of dapsone in dermatology. Int J Dermatol 59(7):787–795. https://doi.org/10.1111/ijd.14761
doi: 10.1111/ijd.14761
pubmed: 31909480
Al-Salama ZT, Deeks ED (2017) Dapsone 7.5% gel: a review in Acne Vulgaris. Am J Clin Dermatol 18(1):139–145. https://doi.org/10.1007/s40257-016-0242-0
doi: 10.1007/s40257-016-0242-0
pubmed: 28005194
Basendwh MA, Alharbi AA, Bukhamsin SA, Abdulwahab RA, Alaboud SA (2024) The efficacy of topical clascoterone versus systematic spironolactone for treatment of acne vulgaris: a systematic review and network meta-analysis. PLoS ONE 19(5):e0298155. https://doi.org/10.1371/journal.pone.0298155
doi: 10.1371/journal.pone.0298155
pubmed: 38814916
pmcid: 11139337
Chottawornsak N, Chongpison Y, Asawanonda P, Kumtornrut C (2019) Topical 2% ketoconazole cream monotherapy significantly improves adult female acne: a double-blind, randomized placebo-controlled trial. J Dermatol 46(12):1184–1189. https://doi.org/10.1111/1346-8138.15113
doi: 10.1111/1346-8138.15113
pubmed: 31599059
Peterson H, Kircik L, Armstrong AW (2023) Clascoterone cream 1%: mechanism of Action, Efficacy, and Safety of a Novel, First-in-class Topical Antiandrogen Therapy for Acne. J Drugs Dermatol 22(6):SF350992s7–SF350992s14
pubmed: 37276168
Shaw JC (1991) Spironolactone in dermatologic therapy. J Am Acad Dermatol 24(2 Pt 1):236–243. https://doi.org/10.1016/0190-9622(91)70034-y
doi: 10.1016/0190-9622(91)70034-y
pubmed: 1826112
Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ (2017) Oral spironolactone for Acne Vulgaris in Adult females: a hybrid systematic review. Am J Clin Dermatol 18(2):169–191. https://doi.org/10.1007/s40257-016-0245-x
doi: 10.1007/s40257-016-0245-x
pubmed: 28155090
pmcid: 5360829
Dhurat R, Shukla D, Lim RK, Wambier CG, Goren A (2021) Spironolactone in adolescent acne vulgaris. Dermatol Ther 34(1):e14680. https://doi.org/10.1111/dth.14680
doi: 10.1111/dth.14680
pubmed: 33326148
Rehan ST, Khan Z, Abbas S et al (2023) Role of topical spironolactone in the treatment of acne: a systematic review of clinical trials-does this therapy open a path towards favorable outcomes? J Dermatol 50(2):166–174. https://doi.org/10.1111/1346-8138.16637
doi: 10.1111/1346-8138.16637
pubmed: 36412248
Adityan B, Kumari R, Thappa DM (2009) Scoring systems in acne vulgaris. Indian J Dermatol Venereol Leprol 75(3):323–326. https://doi.org/10.4103/0378-6323.51258
doi: 10.4103/0378-6323.51258
pubmed: 19439902
Gollnick H, Cunliffe W, Berson D et al (2003) Management of acne: a report from a Global Alliance to Improve outcomes in Acne. J Am Acad Dermatol 49(1 Suppl):S1–S37. https://doi.org/10.1067/mjd.2003.618
doi: 10.1067/mjd.2003.618
pubmed: 12833004
Hebert A, Thiboutot D, Stein Gold L et al (2020) Efficacy and Safety of Topical Clascoterone Cream, 1%, for treatment in patients with facial acne: two phase 3 Randomized clinical trials. JAMA Dermatol 156(6):621–630. https://doi.org/10.1001/jamadermatol.2020.0465
doi: 10.1001/jamadermatol.2020.0465
pubmed: 32320027
Noaimi A, Al-Saadi SR (2021) Treatment of Acne Vulgaris by Topical Spironolactone Solution compared with clindamycin solution. Cureus 13(8):e17606. https://doi.org/10.7759/cureus.17606
doi: 10.7759/cureus.17606
pubmed: 34646657
pmcid: 8483163
van der Heijden CDCC, Deinum J, Joosten LAB, Netea MG, Riksen NP (2018) The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis. Cardiovasc Res 114(7):944–953. https://doi.org/10.1093/cvr/cvy092
doi: 10.1093/cvr/cvy092
pubmed: 29668907
Ayatollahi A, Samadi A, Bahmanjahromi A, Robati RM (2021) Efficacy and safety of topical spironolactone 5% cream in the treatment of acne: a pilot study. Health Sci Rep 4(3):e317. https://doi.org/10.1002/hsr2.317
doi: 10.1002/hsr2.317
pubmed: 34250269
pmcid: 8247934
Afzali BM, Yaghoobi E, Yaghoobi R, Bagherani N, Dabbagh MA (2012) Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial. J Dermatolog Treat 23(1):21–25. https://doi.org/10.3109/09546634.2010.488260
doi: 10.3109/09546634.2010.488260
pubmed: 20964565
Kelidari HR, Saeedi M, Hajheydari Z et al (2016) Spironolactone loaded nanostructured lipid carrier gel for effective treatment of mild and moderate acne vulgaris: a randomized, double-blind, prospective trial. Colloids Surf B Biointerfaces 146:47–53. https://doi.org/10.1016/j.colsurfb.2016.05.042
doi: 10.1016/j.colsurfb.2016.05.042
pubmed: 27248464
Pickert A, Raimer S (2009) An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert Opin Pharmacother 10(9):1515–1521. https://doi.org/10.1517/14656560903002097
doi: 10.1517/14656560903002097
pubmed: 19505219
Tanghetti E, Dhawan S, Green L et al (2011) Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J Drugs Dermatol 10(7):783–792
pubmed: 21720661
Faghihi G, Rakhshanpour M, Abtahi-Naeini B, Nilforoushzadeh MA (2014) The efficacy of 5% dapsone gel plus oral isotretinoin versus oral isotretinoin alone in acne vulgaris: a randomized double-blind study. Adv Biomed Res 3:177. https://doi.org/10.4103/2277-9175.139413
doi: 10.4103/2277-9175.139413
pubmed: 25250291
pmcid: 4166047
Lucky AW, Maloney JM, Roberts J et al (2007) Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol 6(10):981–987
pubmed: 17966175